ACRS News and Press, Aclaris Therapeutics Inc. From 02/10/20

WAYNE, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Confere...

Acasti Pharma (NASDAQ: ACST )  -66%  after  unsuccessful results  from a Phase 3 TRILOGY 1 trial. More news on: Acasti Pharma Inc., Stage Stores, Inc., Five Below, Inc., Stocks on the move, Read more ...

Sorrento Therapeutics (NASDAQ: SRNE ) +50%  on non-binding takeover bid . More news on: Sorrento Therapeutics, Inc., Aclaris Therapeutics, Inc., AzurRx BioPharma, Inc., Stocks on the move, Read more ...

Are These Penny Stocks On Your Friday Morning Watch List? Friday, January 10 marks the end of the first full week of 2020 and there are several economic reports to take into account. These include employment, nonfarm payrolls, and business inventories. These will all be reported throughout the...

Aclaris Therapeutics (NASDAQ: ACRS ) is up 19.9% after hours following positive results from its Phase 1 trial of ATI-450, an investigational oral MK2 inhibitor. More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

•   Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6 •   Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aclaris...

WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent Milano to its board of directors, effective January 7, 2020. Vincent Mila...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

Editor's note: Seeking Alpha is proud to welcome ARCLeaf LLC as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Editor's note: Seekin...

WAYNE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at the following conferences: Dr. Neal Walker, President and Chief Exe...